PDCD1 and neoplasm: This combination effectively induces systemic anti-tumor immune responses, elevating CD8+ T cell infiltration and systemic IFN-γ secretion, enhancing the accumulation of effector memory CD8+ T lymphocytes, further strengthening the efficacy of PD-1 blockade therapy [428].